The Sleep Disorders Channel is supported through educational grants from Alkermes and Takeda.
VJNeurology is an independent medical education platform. Channel supporters have no influence over the production of content.
SLEEP 2026 | New AASM guidelines for RLS recommend against the use of dopamine agonists
Michael Mak, MD, FRCPC, DRCPSC, FCPA, FAASM, University of Toronto, Toronto, Canada, discusses updates to the American Academy of Sleep Medicine (AASM) guidelines for restless legs syndrome, recommending against the use of dopamine agonists. Dr Mak recommends alpha-2 delta ligands as first-line treatments instead. This interview took place at the 40th annual meeting of the Associated Professional Sleep Societies (APSS) in Baltimore, MD.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
